Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Has announcements × Recurrence × Doxorubicin × Clear all

Sponsor

Conditions

Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Lymphoma, T-Cell 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, B-Cell 1 Lymphoma 1 Hematologic Diseases 1 Endometrial Neoplasms 1 Burkitt Lymphoma 1 Ann Arbor Stage IIB Hodgkin Lymphoma 1

Interventions

tisagenlecleucel 2 blinatumomab 2 zanubrutinib 1 selinexor 1 revumenib 1 niraparib 1 nilotinib 1 ivosidenib 1 imetelstat 1 idecabtagene vicleucel 1 ibrutinib 1 fludarabine 1 entrectinib 1 dostarlimab 1 avapritinib 1 asciminib 1 Standard of Care 1 Paclitaxel 1 Imatinib Mesylate 1 GRN163L peptide 1 Drug Therapy 1 Dexamethasone 1 Dasatinib 1 Cyclophosphamide 1 Carboplatin 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡